Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

134 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Gain of chromosome arm 9p is characteristic of primary mediastinal B-cell lymphoma (MBL): comprehensive molecular cytogenetic analysis and presentation of a novel MBL cell line.
Bentz M, Barth TF, Brüderlein S, Bock D, Schwerer MJ, Baudis M, Joos S, Viardot A, Feller AC, Müller-Hermelink HK, Lichter P, Döhner H, Möller P. Bentz M, et al. Among authors: viardot a. Genes Chromosomes Cancer. 2001 Apr;30(4):393-401. doi: 10.1002/1098-2264(2001)9999:9999<::aid-gcc1105>3.0.co;2-i. Genes Chromosomes Cancer. 2001. PMID: 11241792
Further delineation of chromosomal consensus regions in primary mediastinal B-cell lymphomas: an analysis of 37 tumor samples using high-resolution genomic profiling (array-CGH).
Wessendorf S, Barth TF, Viardot A, Mueller A, Kestler HA, Kohlhammer H, Lichter P, Bentz M, Döhner H, Möller P, Schwaenen C. Wessendorf S, et al. Among authors: viardot a. Leukemia. 2007 Dec;21(12):2463-9. doi: 10.1038/sj.leu.2404919. Epub 2007 Aug 30. Leukemia. 2007. PMID: 17728785
Microarray-based genomic profiling reveals novel genomic aberrations in follicular lymphoma which associate with patient survival and gene expression status.
Schwaenen C, Viardot A, Berger H, Barth TF, Bentink S, Döhner H, Enz M, Feller AC, Hansmann ML, Hummel M, Kestler HA, Klapper W, Kreuz M, Lenze D, Loeffler M, Möller P, Müller-Hermelink HK, Ott G, Rosolowski M, Rosenwald A, Ruf S, Siebert R, Spang R, Stein H, Truemper L, Lichter P, Bentz M, Wessendorf S; Molecular Mechanisms in Malignant Lymphomas Network Project of the Deutsche Krebshilfe. Schwaenen C, et al. Among authors: viardot a. Genes Chromosomes Cancer. 2009 Jan;48(1):39-54. doi: 10.1002/gcc.20617. Genes Chromosomes Cancer. 2009. PMID: 18828156
CD5+ B cells from individuals with systemic lupus erythematosus express granzyme B.
Hagn M, Ebel V, Sontheimer K, Schwesinger E, Lunov O, Beyer T, Fabricius D, Barth TF, Viardot A, Stilgenbauer S, Hepp J, Scharffetter-Kochanek K, Simmet T, Jahrsdörfer B. Hagn M, et al. Among authors: viardot a. Eur J Immunol. 2010 Jul;40(7):2060-9. doi: 10.1002/eji.200940113. Eur J Immunol. 2010. PMID: 20394077 Free article.
Limited clinical relevance of imaging techniques in the follow-up of patients with advanced chronic lymphocytic leukemia: results of a meta-analysis.
Eichhorst BF, Fischer K, Fink AM, Elter T, Wendtner CM, Goede V, Bergmann M, Stilgenbauer S, Hopfinger G, Ritgen M, Bahlo J, Busch R, Hallek M; German CLL Study Group (GCLLSG). Eichhorst BF, et al. Blood. 2011 Feb 10;117(6):1817-21. doi: 10.1182/blood-2010-04-282228. Epub 2010 Dec 7. Blood. 2011. PMID: 21139079 Free article.
Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia.
Topp MS, Gökbuget N, Zugmaier G, Klappers P, Stelljes M, Neumann S, Viardot A, Marks R, Diedrich H, Faul C, Reichle A, Horst HA, Brüggemann M, Wessiepe D, Holland C, Alekar S, Mergen N, Einsele H, Hoelzer D, Bargou RC. Topp MS, et al. Among authors: viardot a. J Clin Oncol. 2014 Dec 20;32(36):4134-40. doi: 10.1200/JCO.2014.56.3247. Epub 2014 Nov 10. J Clin Oncol. 2014. PMID: 25385737 Clinical Trial.
Long-term survival and T-cell kinetics in relapsed/refractory ALL patients who achieved MRD response after blinatumomab treatment.
Zugmaier G, Gökbuget N, Klinger M, Viardot A, Stelljes M, Neumann S, Horst HA, Marks R, Faul C, Diedrich H, Reichle A, Brüggemann M, Holland C, Schmidt M, Einsele H, Bargou RC, Topp MS. Zugmaier G, et al. Among authors: viardot a. Blood. 2015 Dec 10;126(24):2578-84. doi: 10.1182/blood-2015-06-649111. Epub 2015 Oct 19. Blood. 2015. PMID: 26480933 Free PMC article.
134 results